Deals In Depth: November 2020 :: Generics Bulletin
Sage Therapeutics Forges $575 Million Deal With Shionogi to Market Depression Drug in Parts of Asia | BioSpace
SY Investing on Twitter: "$SAGE (-62% PM) announced pivotal Ph 3 MOUNTAIN results of SAGE-217 in MDD. Study didn't meet primary endpoint. #Fail SAGE- 217 showed mean reduction of 12.6 in HAM-D total
Sage surges after depression drug gets rapid path to approval - PMLiVE
Sage advice: psychiatric drug development is tough | Evaluate
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration | Business Wire
Sage advice: psychiatric drug development is tough | Evaluate
Sage Therapeutics surges 70% after depression drug breakthrough
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) | Business Wire
Biogen and Sage Therapeutics Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Biogen
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
PDF) Sage Therapeutics-Sitting On The Brink Of CNS Breakthroughs
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder - Chemdiv
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
sage-10k_20191231.htm
Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
sage-10k_20161231.htm
Defensive Strategies For Sage Therapeutics In The Aftermath Of Potential SAGE-547 Regulatory Action (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
BioWorld
